MedTrace Logo

Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma

NCT02077114 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2014-09-26

No results posted yet for this study

Summary

The purpose of the study is to assess whether a vaccine containing a small fragment of the protein IDO, which may be present in cancer cells and cells of the immune system, is safe to use in combination with either Ipilimumab or Vemurafenib in the treatment of malignant melanoma that has metastasized.

Conditions

  • Malignant Melanoma With Metastasis

Interventions

BIOLOGICAL

Vaccine consisting of a peptide derived from the protein IDO

All patients will receive seven vaccines containing IDOlong

Sponsors & Collaborators

  • Herlev Hospital

    lead OTHER

Principal Investigators

  • Jon Bjørn, MD · Center for Cancer Immune Therapy

  • Inge Marie Svane, MD, PhD, Professor · Center for Cancer Immune Therapy

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02077114 on ClinicalTrials.gov